Preliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Model

Jennifer Lambraño, Hernando Curtidor, Catalina Avendaño, Diana Díaz-Arévalo, Leonardo Roa, Magnolia Vanegas, Manuel E. Patarroyo, and Manuel A. Patarroyo

1Fundación Instituto de Inmunología de Colombia (FIDIC), Bogotá, Colombia
2Master’s Programme in Biochemistry, Medical School, Universidad Nacional de Colombia, Bogotá, Colombia
3Faculty of Animal Science, Universidad de Ciencias Aplicadas y Ambientales (U.D.C.A), Bogotá, Colombia
4School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia
5Pathology Department, Medical School, Universidad Nacional de Colombia, Bogotá, Colombia

Correspondence should be addressed to Manuel A. Patarroyo; mapatarr.fidic@gmail.com

Received 3 October 2019; Accepted 3 December 2019; Published 30 December 2019

Academic Editor: Pedro A. Reche

Copyright © 2019 Jennifer Lambraño et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Malaria continues being a high-impact disease regarding public health worldwide; the WHO report for malaria in 2018 estimated that ~219 million new malaria-related cases occurred in 2017, mostly caused by the parasite Plasmodium falciparum. The disease cost the lives of more than 400,000 people, mainly in Africa. In spite of great efforts aimed at developing better prevention (i.e., a highly effective vaccine), diagnosis, and treatment methods for malaria, no efficient solution to this disease has been advanced to date. The Fundación Instituto de Inmunología de Colombia (FIDIC) has been developing studies aimed at furthering the search for vaccine candidates for controlling P. falciparum malaria. However, vaccine development involves safety and immunogenicity studies regarding their formulation in animal models before proceeding to clinical studies. The present work has thus been aimed at evaluating the safety and immunogenicity of a mixture of 23 chemically synthesised, modified peptides (immune protection-inducing protein structure (IMPIPS)) derived from different P. falciparum proteins. Single and repeat dose assays were thus used with male and female BALB/c mice which were immunised with the IMPIPS mixture. It was found that single and repeat dose immunisation with the IMPIPS mixture was safe, both locally and systemically. It was observed that the antibodies so stimulated recognised the parasite’s native proteins and inhibited merozoite invasion of red blood cells in vitro when evaluating the humoral immune response induced by the IMPIPS mixture. Such results suggested that the IMPIPS peptide mixture could be a safe candidate to be tested during the next stage involved in developing an antimalarial vaccine, evaluating local safety, immunogenicity, and protection in a nonhuman primate model.

1. Introduction

Malaria represents one of the greatest public health problems worldwide. According to the World Health Organization (WHO), ~219 million new malaria-related cases occurred in 2017 accompanied by ~435,000 deaths. The African continent was the most affected region in the world (92% of cases and 93% of deaths) [1]. The Global Technical Strategy for Malaria 2016-2030 (WHO) has suggested reducing malarial incidence and mortality by at least 90% and eliminating it in at least 35 countries by 2030 through prevention, diagnosis, and treatment strategies [2].

No significant progress has been observed to date regarding the reduction of cases of malaria worldwide despite the differing strategies used for combating this disease (using insecticide-impregnated mosquito nets for controlling the vector, chemophylaxis, and case management) [1, 2]. The most recurrent problem is concerned with the increase
immune protection-inducing protein structures (IMPIPS) in view of their close structure-protection report [3, 34–38] of a mixture of 23 IMPIPS. These were derived from the main \( P. \) falciparum [39, 40], as well as Mrz proteins (apical membrane antigen-1 (AMA-1), erythrocyte-binding protein 175 (EBA-175), erythrocyte-binding protein 140 (EBA-140), serine repeat antigen (SERA-5), merozoite surface protein-1 (MSP-1), and histidine-rich protein II (HRP-II)) [10, 39, 40], as well as Mrz proteins (apical membrane antigen-1 (AMA-1), erythrocyte-binding protein 175 (EBA-175), erythrocyte-binding protein 140 (EBA-140), serine repeat antigen (SERA-5), merozoite surface protein-1 (MSP-1), and histidine-rich protein II (HRP-II)) [10, 39, 40]. Previous studies testing these peptides individually have shown that the antibodies induced were able to recognise the original template protein when expressed as a recombinant (Supplementary Table 1).

2. Materials and Methods

2.1. Peptide Synthesis and Purification. Twenty-three polymer peptides (Table 1) were modified following previously reported principles [32, 33, 40, 41] to render them immunogenic and then synthesised using solid-phase multiple peptide synthesis following the tert-butylxycarbonyl (t-Boc) synthesis strategy described by Merrifield [42] and modified by Houghten [43]. All peptides were derived from fully conserved and functionally relevant regions of the corresponding proteins. Such a Merck-Hitachi L-6200 A chromatograph (Merck) fitted with a UV-VIS L-4250 210 nm wavelength detector was used for determining synthesised peptide purity by high-performance reversed-phase liquid chromatography. A Microflex mass spectrometer (Bruker Daltonics) was then used for characterising them by matrix-assisted laser desorption/ionisation-time of flight (MALDI-TOF).

2.2. Animals. Forty BALB/c mice (20 males and 20 females) were used for evaluating the formulation’s safety and immunogenicity. The mice were aged 5 to 6 weeks when they were immunised, according to WHO recommendations [37]. The mice were acquired from the Universidad Nacional de Colombia’s Faculty of Animal Science’s Bioterium.

2.2.1. Single Dose Local Tolerance. This assay enabled determining possible inflammatory reactions at the different treatments’ inoculation sites [37]; this involved using 18 BALB/c mice (9 males and 9 females), following the protocols established by the regulatory authorities [34–37]. The animals were randomly assigned to 3 groups (Table 2), each consisting of 3 males and 3 females, in line with the principles of reduction and refinement [44].

The animals were immunised by subcutaneous (SC) route at the base of the tail with 100 \( \mu L \) of the formulation. The animals were observed twice a day after they had been immunised for detecting changes in their behaviour, signs of disease, or toxicity. The injection site and the tissue around it were examined 1, 3, 24, 48, and 72 hours after immunisation to ascertain the presence of erythema, oedema, eschar, and necrosis; the parameters described by Cox were used for evaluating their degree [45]. The animals were anesthetised with ketamine (80–120 mg/kg) and xylazine (5–16 mg/kg) by intraperitoneal (IP) route on the third day and sacrificed by cervical dislocation.

2.2.2. Repeat Doses. Twenty-two BALB/c 5- to 6-week-old mice (11 males and 11 females) were randomly distributed into three groups for evaluating possible toxic reactions produced by repeat inoculations (SC) of the Pf-IMPIPS peptide mixture (30 \( \mu g \) in total). Toxicity due to repeat doses can occur as a result of repeat administration of a product over a specific period [35–37] (Table 3).

The animals were immunised 4 times with a 14-day interval as the amount of doses in an animal model must be equal to or greater than the amount of doses for clinical assays [37],
and it would be expected that the amount of doses administered would not exceed two in clinical assays (Figure 1). Each group was immunised with 100 μL of the formulation on days 0, 14, 28, and 42; the formulation was administered by SC route at the base the tail. The immunisation sites were examined 1, 3, and 24 h after each injection looking for signs of erythema, oedema, eschar, and necrosis.

The animals were observed twice per day for evidence of any adverse reaction to the injection or the presence of disease, and a weekly physical examination was made for monitoring every animal’s overall state of health. Their weight and food consumption were also monitored before beginning the immunisation protocol and after immunisation on days 0, 3, and 7 and every week thereafter until day 70.

Mouse body temperature was measured with an infrared thermometer (Benetech GM320) before and after each immunisation (0, 4, and 24 h) at five different sites on their abdomens. The average of five readings was recorded [46].

Blood samples were taken from the facial vein before immunisation and on days 1, 3, 40, 43, and 70 following the first immunisation to rule out acute and chronic alterations and in case of any abnormal findings. These samples were used for evaluating blood urea nitrogen (BUN), creatinine (CRE), haematocrit (HCT), red blood cell (RBC) count, white blood cell (WBC) count, and total plasma protein.

### Table 1: List of peptides (IMPIPS) included in the mixture.

| mHABP | Sequence | Protein | Theoretical mass (kDa) | Mass (m/z) |
|-------|----------|---------|------------------------|-----------|
| 32958 | CGGNNGQGLNMMNPFPNFLDENAGC | CSP | 2,436.8 | 2,436.9 |
| 25608 | CGKNSFLGENPNAPGC | CSP | 1,809.3 | 1,807.1 |
| 24312 | CGDLGQNGRDMNIVDENKYGC | TRAP | 2,715.4 | 2,713.3 |
| 24242 | CGVWDESWVSTAVMGNTRSKGC | TRAP | 2,568.8 | 2,567.3 |
| 24250 | CGKSLDIERKMDAQPQDNINGC | TRAP | 2,393.8 | 2,392.2 |
| 24254 | CGGAATPSGEPSPFDVLEGEENGCR | TRAP | 2,372.9 | 2,373.2 |
| 4320 | CGVHKRFHADYQAPFLLLGGGYGC | STARP | 2,628.8 | 2,626.0 |
| 38150 | CGTDLILKALKLQNTNKGCR | SPECT | 2,090.9 | 2,089.3 |
| 38890 | CGSDYTALAAEKVSYWIGCRC | SPECT-2 | 2,435.1 | 2,436.2 |
| 38128 | CGKMRPSDSDFDSDTSESFDYKC | SPECT-2 | 2,612.3 | 2,611.7 |
| 38976 | CGVNTTVSGVSNLHSVAEDGGC | SPECT-2 | 2,316.0 | 2,316.3 |
| 38880 | CGTAVGALQADWNYNTGCR | CELTOS | 2,212.9 | 2,213.9 |
| 38162 | CGKQTQGHSYHLRKNGKHPVYGC | SIAP-1 | 2,726.6 | 2,729.2 |
| 38884 | CGGLHYSTDQSQPNLSDGFGLGC | SIAP-2 | 2,411.0 | 2,411.3 |
| 13486 | CGMIKAFDPTFAGSKPRYKSHGC | AMA-1 | 2,589.6 | 2,588.8 |
| 37206 | CGNDKLYFDYWKVKKDGC | EBA-175 | 2,425.2 | 2,405.3 |
| 24292 | CGLTNQNDINTEENLMKHFGHGC | EBA-175 | 2,734.4 | 2,732.0 |
| 22690 | CGNNPSPSYLDYLMDDLDGC | EBA-175 | 2,405.2 | 2,402.2 |
| 36620 | CGULKSETKDYDMFQSKIDSFLGC | EBA-140 | 2,785.6 | 2,781.7 |
| 22796 | CGDNILVMKFMKFIYNEKDELGC | SERA | 2,683.6 | 2,681.7 |
| 23426 | CGKTVQNLGTDDTAULATINNVGTC | SERA | 2,394.0 | 2,395.4 |
| 10014 | CGEVLYHVPLAVYRSLKQLEGCG | MSP-1 | 2,663.5 | 2,662.9 |
| 24230 | CGSAEDNLTANAMGLLIGNKRGC | HRP-2 | 2,456.4 | 2,453.4 |

m/z: mass-to-charge ratio.

### Table 2: Single dose: distribution of the groups of mice according to treatment.

| Treatment | Size |
|-----------|------|
| Group 1   | Physiological saline solution (PSS) (control) | 3M+3F |
| Group 2   | IMPIPS mixture (30 μg in total)+PSS (1 : 1) | 3M+3F |
| Group 3   | IMPIPS mixture (30 μg in total)+Freund’s adjuvant* (1 : 1) | 3M+3F |

*The immunisation was made with complete Freund’s adjuvant.

### Table 3: Repeat doses: distribution of the groups of mice according to treatment.

| Treatment | Size |
|-----------|------|
| Group 1   | Physiological saline solution (PSS) (control) | 3M+3F |
| Group 2   | IMPIPS mixture+PSS (1 : 1) | 4M+4F |
| Group 3   | IMPIPS mixture+Freund’s adjuvant* (1 : 1) | 4M+4F |

*The first immunisation was made with complete Freund’s adjuvant and those thereafter with Freund’s incomplete adjuvant.

and it would be expected that the amount of doses administered would not exceed two in clinical assays (Figure 1). Each group was immunised with 100 μL of the formulation on days 0, 14, 28, and 42; the formulation was administered by SC route at the base the tail. The immunisation sites were examined 1, 3, and 24 h after each injection looking for signs of erythema, oedema, eschar, and necrosis.

The animals were observed twice per day for evidence of any adverse reaction to the injection or the presence of disease, and a weekly physical examination was made for monitoring every animal’s overall state of health. Their weight and food consumption were also monitored before beginning the immunisation protocol and after immunisation on days 0, 3, and 7 and every week thereafter until day 70.

Mouse body temperature was measured with an infrared thermometer (Benetech GM320) before and after each immunisation (0, 4, and 24 h) at five different sites on their abdomens. The average of five readings was recorded [46].

Blood samples were taken from the facial vein before immunisation and on days 1, 3, 40, 43, and 70 following the first immunisation to rule out acute and chronic alterations and in case of any abnormal findings. These samples were used for evaluating blood urea nitrogen (BUN), creatinine (CRE), haematocrit (HCT), red blood cell (RBC) count, white blood cell (WBC) count, and total plasma protein.
1. Introduction

1.1. Objective

The objective of this study is to evaluate the effects of IMPIPS on parasite proliferation and to determine the ability of IMPIPS to inhibit the invasion of erythrocytes by the parasite, considering the potential of IMPIPS to be a candidate for a vaccine against Plasmodium falciparum.

2. Materials and Methods

2.1. Parasites

The Plasmodium falciparum PFCB-2 strain was used for all experiments. The parasites were maintained in a 37°C incubator (5% CO₂) and 90% N₂ atmosphere.

2.2. Parasite Culture

 Parasite culture was performed in RPMI 1640 media (Gibco) supplemented with 10% (v/v) human plasma.

2.3. Serum from Immunised Mice

Serum from immunised mice was used for the invasion inhibition assay. Serum from immunised mice was pooled due to the limited volume available.

2.4. Evaluation of Parasite Invasion

The invasion inhibition assay was performed using 384-well plates seeded with 1.7 μL/well parasite culture (2% haematocrit and 0.1% parasitaemia) incubated with serum from the final bleeding day at various concentrations (20%, 10%, 5%, and 2.5% v/v/v). The plate was incubated at 37°C for 48 h in a 5% O₂, 5% CO₂, and 90% N₂ atmosphere. Parasite culture supplemented with healthy human plasma was used as the culture control.

3. Results

3.1. Parasite Invasion Inhibition

The results showed that serum from immunised mice inhibited the invasion of erythrocytes by the parasite. The assay was made by pooling all the sera from each group due to the low serum volume available.

4. Conclusion

The results suggest that IMPIPS could be a potential candidate for a vaccine against Plasmodium falciparum. Further studies are needed to determine the protective efficacy of IMPIPS in vivo and its ability to induce a controlled immune response.

Figure 1: Immunisation scheme for evaluating local tolerance and systemic toxicity due to repeat doses in mice.
2.4. Statistical Analysis. GraphPad Prism 7 software was used for statistically analysing the data for each group of animals (minimum and maximum values, the mean and standard deviation (SD)). The Shapiro-Wilk test of normality was used for comparing the groups of animals according to treatment; ANOVA was then used for analysing normally distributed data, whilst nonnormally distributed data was analysed by the Tukey or Kruskal-Wallis multiple comparison test and Dunn’s multiple comparison test. Differences were considered statistically significant at \( p < 0.05 \). Stata software’s linear regression model was used for statistically analysing histopathological results, using Pearson’s \( X^2 \) test, for determining whether the IMPIPS mixture was toxic for the organs and tissues analysed here.

2.5. Ethical Statements. The mice were maintained according to the bioethical regulations laid down in Colombian Law 84/1989 [52], Colombian Ministry of Health resolution 8430/1993 [53], and the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health [54]. Regulations stipulated by the American Veterinary Medical Association’s (AVMA) Panel on Euthanasia (2013) were also considered [47]. All the animals were fed on Rodent Diet 5010 (LabDiet) and provided with water ad libitum. The Universidad de Ciencias Aplicadas y Ambientales (U.D.C.A) ethics committee, regulated by Agreement 285/2008, Chapter VII, endorsed this research.

3. Results

3.1. Local Tolerance: Single Dose in Mice. No deaths occurred in any of the groups being studied for this assay. None of the animals (females or males) in the different groups treated and evaluated 1, 3, 24, 48, and 72 h postimmunisation had lesions at the inoculation site, compared to the control group (not immunised).

3.2. Local and Systemic Tolerance: Repeat Doses in Mice. There were no deaths in any of the groups of animals when evaluating local toxicity due to repeat doses of the IMPIPS mixture. No local adverse reactions were observed (postimmunisation), such as oedema, eschar, or necrosis, at the inoculation site in any of the groups.

3.2.1. Physiological Parameters. The Shapiro-Wilk test of normality confirmed a normal distribution for male and female weight values. Average weight gain according to the means for each experimental group and the SD (mean ± SD) obtained for each treatment for male mice immunised with PSS, IMPIPS+PSS, and MPIPS+adjuvant was 25.32 ± 2.56 g, 25.01 ± 3.06 g, and 23.34 ± 3.38 g, respectively, whilst for the females immunised with just PSS, IMPIPS+PSS, and IMPIPS+adjuvant, this was 19.70 ± 1.99 g, 19.23 ± 2.39 g, and 19.38 ± 3.01, respectively (Supplementary Figure 1). Statistical analysis revealed no significant differences between the groups \( (p > 0.05) \).

Mean weekly consumption of food by the males immunised with PSS, IMPIPS+PSS, and MPIPS+adjuvant was 30.69 ± 1.43 g, 30.2 ± 1.25 g, and 30.97 ± 2.99 g, respectively, compared to the females immunised with PSS, IMPIPS+PSS, and MPIPS+adjuvant (24.05 ± 1.25 g, 24.88 ± 1.20 g, and 25.27 ± 1.72 g, respectively) (Supplementary Figure 1). Statistical analysis did not reveal any significant differences between the groups \( (p > 0.05) \).

3.2.2. Haematological Parameters. The haematic picture evaluated parameters related to erythrocytes (erythrocyte count (RBC), haematocrit (HCT), haemoglobin (Hb), and total plasma proteins (TPP)) and leukocytes (leukocyte (WBC) count) for determining possible alterations caused by the formulation. The reference values for analysing each biochemical parameter were determined by mean control ± SD; no significant differences \( (p > 0.05) \) were observed regarding either erythrocytes or leukocytes. Complete blood cell count (CBC) values came within the stated parameters, except for day 3 when control group females had a slight reduction in haematocrit and haemoglobin, possibly due to previous bleedings. By contrast, an increase in leukocytes was observed in control group males; this increase could have been caused by stress due to the bleeding.

Renal function was evaluated by measuring BUN and CRE. ANOVA analysis identified no statistically significant differences between the different treatments when comparing values between the groups or when comparing control group values (saline solution) to those for the other study groups \( (p > 0.05) \) (Figure 2). The reference values for analysing each biochemical parameter were determined from the means for the controls ± SD (Figure 2).

3.2.3. Histopathology. Microcirculatory changes related to slight and moderate vascular congestion were observed in the myocardium in 2/4 females immunised with the IMPIPS+adjuvant formulation; there was no evidence of congestion in the other animals from the same group or from the other groups \( (p > 0.05) \). No microcirculatory changes were seen in any of the immunised animals, such as oedema and/or haemorrhage, inflammatory infiltrate, structural changes, or binucleation (Figure 3).

Slight congestion was observed in the kidneys of at least one animal from every group. These changes occurred more in females than in males, since a lesion was found in just one male compared to 6 females (2 from each group) in which congestion was observed. No microcirculatory changes such as oedema and haemorrhage, inflammatory infiltrate, structural changes, or binucleations were observed in any of the study groups (Figure 4).

No macroscopic or microscopic alterations were observed when analysing the duodenum, though 50% of the mice immunised with IMPIPS+adjuvant had mixed inflammatory infiltrate in the mesentery (Figure 5). Likewise, follicular...
hyperplasia was observed in 100% of the mice immunised with IMPIPS+adjuvant when analysing lymphoid tissue, 50% being slight and 50% moderate. 37.5% of the mice immunised with IMPIPS+PSS had this reaction to a slight degree and 25% to a moderate degree. Two (33.3%) control group mice had slight follicular hyperplasia (Figure 6).

Figure 2: Means for the biochemical parameters: blood urea nitrogen (BUN) and creatinine (CRE). BUN and CRE values are shown for females (a and c) and males (b and d), according to time elapsed and group immunised. The horizontal dotted lines indicate the reference values.

Figure 3: Histological section of the myocardium on day 70, stained with haematoxylin-eosin: (a) histology for the normal myocardium in a mouse treated with physiological saline solution (100x); (b) section of the myocardium from a mouse belonging to the group immunised with IMPIPS+adjuvant; microcirculatory changes related to moderate vascular congestion were observed (100x).
Figure 4: Histological section of the kidney on day 70, stained with haematoxylin-eosin: (a) histology for the normal kidney in a mouse treated with physiological saline solution (400x); (b) section of the kidney from a mouse from the group immunised with IMPIPS +adjuvant had microcirculatory changes regarding slight congestion (arrow) (400x).

Figure 5: Histological section of the mouse mesentery on day 70, stained with haematoxylin-eosin: (a) histology for the normal mesentery of a mouse treated with saline solution (400x); (b) mesentery having mixed inflammatory infiltrate from a mouse treated with IMPIPS+adjuvant (400x).

Figure 6: Histological section of mouse lymphoid tissue on day 70, stained with haematoxylin-eosin: (a) histology of mouse normal lymphoid tissue treated with saline solution (100x); (b) lymphoid tissue from a mouse treated with IMPIPS+adjuvant having nodular hyperplasia (100x).
scale was generated to semiquantify follicular hyperplasia according to the number of nodules using a magnification of 400x (Supplementary Table 2).

3.3. Immunogenicity

3.3.1. Determining Anti-IMPIPS Serum Ability to Recognise *P. falciparum*-Infected RBC by IFA. An indirect immunofluorescence assay was used for determining anti-IMPIPS serum ability to recognise pRBC. The serum from mice immunised with IMPIPS+adjuvant as well as that from those immunised with IMPIPS+PSS was able to recognise pRBC (Figure 7). Considering that some *P. berghei* proteins share high identity with their *P. falciparum* counterparts, such as enolase [55], the higher fluorescence intensity observed in the positive control might be due to the higher number of proteins being recognised versus just the six blood-stage proteins being recognised from animals immunised with the peptide mixture.

3.3.2. Determining Anti-IMPIPS Antibodies’ Merozoite Invasion Inhibition Capability. The functional role of antibodies stimulated by immunisation with IMPIPS was determined by an in vitro invasion inhibition assay. The serum from animals immunised with the IMPIPS peptide mixture+PSS was able to inhibit invasion, maximum values being 61.84% for males and 68.34% for females. Likewise, the serum from the animals immunised with the IMPIPS peptide mixture+adjuvant had 67.62% maximum invasion inhibition values for males and 70.82% for females. It was found that inhibition was concentration dependent (*p* < 0.05). No statistical difference was observed between inhibition percentages for the females compared to those for the males (*p* > 0.05) (Figure 8). Sera surpassing 70% were considered strong inhibitors, whilst those ranging from 50% to 69% were considered medium-high inhibitors. Those having 30% to 49% were considered medium-low inhibitors, those from 10%-29% are low inhibitors, and those < 9% were considered negative.

4. Discussion

Toxicological studies of the formulation to be used in clinical studies are of the utmost importance when developing vaccines as they provide information about possible adverse effects which might arise due to the formulation, either at the inoculation site or in the different organs and tissues of subjects being vaccinated [37, 38]. This study thus evaluated the safety and immunogenicity of a mixture of 23 modified peptides derived from 8 Spz proteins (CSP-1, TRAP, STARP, SPECT-1 and SPECT-2, CelTOS, and SIAP-1 and SIAP-2) and 6 Mrz proteins (AMA-1, EBA-175, EBA-140, SERA-5, MSP-1, and HRP-II) [9–11] in a murine model as a synthetic antimalarial vaccine candidate.
The single dose local tolerance study was aimed at evaluating the site exposed to the formulation 72 h postimmunisation; no adverse reactions such as erythema, oedema, eschar, or necrosis were observed in the mice immunised with the IMPIPS mixture+PSS or in those immunised with IMPIPS+adjuvant. This suggested that the IMPIPS mixture did not produce local toxic effects due to single dose SC immunisation. The forgoing led to continuing local and systemic tolerance studies regarding repeat doses (4 immunisations) where SC immunisation also did not produce adverse effects such as erythema, oedema, eschar, or necrosis at the administration site, suggesting that repeat IMPIPS doses did not produce irritation or toxicity at the immunisation site.

Male and female mice immunised with the IMPIPS peptide mixture+PSS or IMPIPS+adjuvant gained weight and increased their weekly food consumption, and their body temperature was within established parameters (i.e., regarding the formulation’s systemic effects) [56], thereby supporting the idea that the IMPIPS mixture did not affect physiology.

Blood chemistry analysis showed that creatinine values did not exceed the parameters compared to control values.
during the first bleeding. Creatinine values on day 40 exceeded the parameters; however, they became reduced by day 70, coming within normal parameters for the males. Such transitory increase could have been due to stress or dehydration since, unlike other mammals, mice excrete creatinine in their urine. Once the situation had become resolved, creatinine returned to its normal values [56]. BUN values came within normal parameters. Since no other damage was observed on day 70, the histological study of the kidneys verified that an increase in creatinine was due to prerenal causes and not to renal damage.

Regarding histological analysis, the microcirculatory changes in the myocardium compatible with congestion did not arise from administering the IMPIPS peptide mixture, since control group animals also had this pathology. Such changes could mainly have been due to the hypovolemic shock caused by the final bleeding; this would have occurred because haemorrhagic shock affects tissue perfusion [57].

Mixed inflammatory infiltrate was observed in the histological study of the mesentery; this description refers to localised accumulations of mononuclear and polymorphonuclear cells, indicating the presence of a foreign body in acute phase, i.e., causing the antigenic stimulus to continue. This finding in the animals immunised with IMPIPS+adjuvant and not in those immunised with IMPIPS+PPS or in the control group indicated that the antigen continued being active. This could have been caused by the formation of a deposit at the injection site due to the adjuvant’s mechanism of action (doses 2, 3, and 4 of the formulation were administered by IP route) [58].

The nodular hyperplasia observed in animals’ lymphoid tissue is mainly due to normal lymphoid nodule inflammation in response to an antigen. Such response in this case was triggered by the immunisation; such reaction is also known as reactive lymphoid hyperplasia [59] which, as expected, was much stronger in the animals immunised with the formulation containing IMPIPS+adjuvant.

FIDIC’s previous studies have shown that individual immunisation of IMPIPS in Aotus monkeys has stimulated the production of antibodies which have been able to recognise parasite proteins in their native form and induce a protective immune response, determined by the total absence of parasites in the blood following experimental challenge [30, 32, 33]. The present study highlighted the fact that serum from male and female mice immunised with the IMPIPS mixture+adjuvant or IMPIPS+PPS recognised the parasite in the Mrz stage. This indicated that although the peptides had been modified for their presentation by human MHC-II [27, 29, 31], the mixture was capable of inducing an immune response against the native proteins from which they were derived, even in a murine model, thereby reinforcing the idea of using IMPIPS in an antimalarial vaccine [60]. Such response was seen in the immunofluorescence and invasion inhibition assays.

5. Conclusions

Local tolerance and systemic safety tests regarding single and repeat doses in this study showed no toxicity induced by the IMPIPS mixture in a murine model 70 days after the first immunisation, reaffirming that peptide-based vaccines can represent a safe option. The IMPIPS mixture was immunogenic in a murine model, even when the peptides were designed for human MHC-II. Such results suggested that the IMPIPS mixture is safe and thus further immunogenicity and protection assays in a nonhuman primate model such as the Aotus spp. monkey but delivered with adjuvants authorised for human use are recommended.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

We would like to thank Jason Garry for translating this manuscript. This work was financed by COLCIENCIAS call for projects 725/2015, the Fundación Instituto de Immunología de Colombia (FIDIC), and the Universidad de Ciencias Aplicadas y Ambientales (U.D.C.A).

Supplementary Materials

Supplementary Figure 1: physiological parameters for male and female mice: weight, weekly consumption of food, and body temperature values. Dotted lines show upper and lower normal values. Supplementary Table 1: publications referencing peptides included in the present study, in which the antibodies raised recognise the corresponding protein expressed as a recombinant. Supplementary Table 2: semiquantitative scale of follicular hyperplasia using a 400x magnification. (Supplementary Materials)

References

[1] World Health Organization (WHO), World Malaria Report 2018, Geneva, 2018.
[2] World Health Organization (WHO), Global Technical Strategy for Malaria 2016-2030, 2015.
[3] D. Menard and A. Dondorp, “Antimalarial drug resistance: a threat to malaria elimination,” Cold Spring Harbor Perspectives in Medicine, vol. 7, no. 7, article a025619, 2017.
[4] M. E. Patarroyo and M. A. Patarroyo, “Emerging rules for subunit-based multiantigenic, multistage chemically synthesized vaccines,” Accounts of Chemical Research, vol. 41, no. 3, pp. 377–386, 2008.
[5] M. E. Patarroyo, A. Bermudez, and M. A. Patarroyo, “Structural and immunological principles leading to chemically synthesized, multiantigenic, multistage, minimal subunit-based vaccine development,” Chemical Reviews, vol. 111, no. 5, pp. 3459–3507, 2011.
[6] Z. Bozdech, M. Llinás, B. L. Pulliam, E. D. Wong, J. Zhu, and J. L. DeRisi, “The transcriptome of the intraerythrocytic...
developmental cycle of *Plasmodium falciparum*, *PLoS Biology*, vol. 1, no. 1, p. E5, 2003.

[7] K. Kaiser, K. Matuschewski, N. Camargo, J. Ross, and S. H. Kappe, "Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins," *Molecular Microbiology*, vol. 51, no. 5, pp. 1221–1232, 2004.

[8] E. Lasonder, C. J. Janse, G. J. van Gemert et al., "Proteomic profiling of *Plasmodium* sporozoite maturation identifies new proteins essential for parasite development and infectivity," *PLoS Pathogens*, vol. 4, no. 10, article e1000195, 2008.

[9] J. E. Garcia, A. Puentes, and M. E. Patiarroyo, "Developmental biology of sporozoite-host interactions in *Plasmodium falciparum* malaria: implications for vaccine design," *Clinical Microbiology Reviews*, vol. 19, no. 4, pp. 686–707, 2006.

[10] L. E. Rodriguez, H. Curtidor, M. Urquiza, G. Cifuentes, C. Reyes, and M. E. Patiarroyo, "Intimate molecular interactions of *P. falciparum* merozoite proteins involved in invasion of red blood cells and their implications for vaccine design," *Chemical Reviews*, vol. 108, no. 9, pp. 3656–3705, 2008.

[11] H. Curtidor, M. Vanegas, M. P. Alba, and M. E. Patiarroyo, "Functional, immunological and three-dimensional analysis of chemically synthesised sporozoite peptides as components of a fully-effective antimalarial vaccine," *Current Medicinal Chemistry*, vol. 18, no. 29, pp. 4470–4502, 2011.

[12] M. Urquiza, L. E. Rodriguez, J. E. Suarez et al., "Identification of *Plasmodium falciparum* MSP-1 peptides able to bind to human red blood cells," *Parasite Immunology*, vol. 18, no. 10, pp. 515–526, 1996.

[13] F. Espejo, M. Cubillos, L. M. Salazar et al., "Structure, immunogenicity, and protective relationship for the 1585 malarial peptide and its substitution analogues," *Angewandte Chemie, International Edition*, vol. 40, no. 24, pp. 4654–4657, 2001.

[14] S. Casares and T. L. Richie, "Immune evasion by malaria parasites: a challenge for vaccine development," *Current Opinion in Immunology*, vol. 21, no. 3, pp. 321–330, 2009.

[15] H. Hisaeda, K. Yasutomo, and K. Himeno, "Malaria: immune evasion by parasites," *The International Journal of Biochemistry & Cell Biology*, vol. 37, no. 4, pp. 700–706, 2005.

[16] M. Hommel, "Antigenic variation in malaria parasites," *Immunology Today*, vol. 6, no. 1, pp. 28–33, 1985.

[17] H. Curtidor, M. Urquiza, J. E. Suarez et al., "*Plasmodium falciparum* acid basic repeat antigen (ABRA) peptides: erythrocyte binding and biological activity," *Vaccine*, vol. 19, no. 31, pp. 4496–4504, 2001.

[18] M. Ocampo, M. Urquiza, F. Guzmán et al., "Two MSA 2 peptides that bind to human red blood cells are relevant to *Plasmodium falciparum* merozoite invasion," *The Journal of Peptide Research*, vol. 55, no. 3, pp. 216–223, 2000.

[19] G. Cifuentes, A. Bermúdez, R. Rodriguez, M. Patiarroyo, and M. Patiarroyo, "Shifting the polarity of some critical residues in malarial peptides binding to host cells is a key factor in breaking conserved antigens code of silence," *Medicinal Chemistry*, vol. 4, no. 3, pp. 278–292, 2008.

[20] F. Guzman, K. Jaramillo, L. M. Salazar, A. Torres, A. Rivera, and M. E. Patiarroyo, "1H-NMR structures of the *Plasmodium falciparum* 1758 erythrocyte binding peptide analogues and protection against malaria," *Life Sciences*, vol. 71, no. 23, pp. 2773–2785, 2002.

[21] L. M. Salazar, M. P. Alba, H. Curtidor et al., "Changing ABRA protein peptide to fit into the HLA-DRβ1*•*0301 molecule renders it protection-inducing," *Biochemical and Biophysical Research Communications*, vol. 322, no. 1, pp. 119–125, 2004.

[22] M. E. Patarroyo, G. Cifuentes, A. Bermúdez, and M. A. Patiarroyo, "Strategies for developing multi-epitope, subunit-based, chemically synthesized anti-malarial vaccines," *Journal of Cellular and Molecular Medicine*, vol. 12, no. 5B, pp. 1915–1935, 2008.

[23] A. Bermúdez, M. P. Alba, M. Vanegas, M. A. Patiarroyo, and M. E. Patiarroyo, "Specific β-turns precede PPII structures binding to allele-specific HLA-DRβ1*•* PBRs in fully-protective malaria vaccine components," *Frontiers in Chemistry*, vol. 6, p. 106, 2018.

[24] C. Reyes, A. Moreno-Vranich, and M. E. Patiarroyo, "The role of pi-interactions and hydrogen bonds in fully protective synthetic malarial vaccine development," *Biochemical and Biophysical Research Communications*, vol. 484, no. 3, pp. 501–507, 2017.

[25] A. Bermúdez, M. P. Alba, M. Vanegas, and M. E. Patiarroyo, "3D structure determination of STARP peptides implicated in *P. falciparum* invasion of hepatic cells," *Vaccine*, vol. 28, no. 31, pp. 4989–4996, 2010.

[26] M. P. Alba, L. M. Salazar, L. E. Vargas, M. Trujillo, Y. Lopez, and M. E. Patiarroyo, "Modifying RESA protein peptide 6671 to fit into HLA-DRβ1*•* pockets induces protection against malaria," *Biochemical and Biophysical Research Communications*, vol. 315, no. 4, pp. 1154–1164, 2004.

[27] M. E. Patiarroyo, G. Cifuentes, C. Piraján, A. Moreno-Vranich, and M. Vanegas, "Atomic evidence that modification of H-bonds established with amino acids critical for host-cell binding induces sterile immunity against malaria," *Biochemical and Biophysical Research Communications*, vol. 394, no. 3, pp. 529–535, 2010.

[28] M. E. Patiarroyo, A. Bermudez, and M. P. Alba, "The high immunogenicity induced by modified sporozoites' malarial peptides depends on their phi (φ) and psi (ψ) angles," *Biochemical and Biophysical Research Communications*, vol. 429, no. 1-2, pp. 81–86, 2012.

[29] M. E. Patiarroyo, H. Almonacid, and A. Moreno-Vranich, "The role of amino acid electron-donor/acceptor atoms in host-cell binding peptides is associated with their 3D structure and HLA-binding capacity in sterile malarial immunity induction," *Biochemical and Biophysical Research Communications*, vol. 417, no. 3, pp. 938–944, 2012.

[30] A. Bermúdez, D. Calderon, A. Moreno-Vranich et al., "Gachte+ side-chain orientation as a key factor in the search for an immunogenic peptide mixture leading to a complete fully protective vaccine," *Vaccine*, vol. 32, no. 18, pp. 2117–2126, 2014.

[31] M. E. Patiarroyo, A. Moreno-Vranich, and A. Bermúdez, "Phi (Φ) and psi (Ψ) angles involved in malarial peptide bonds determine sterile protective immunity," *Biochemical and Biophysical Research Communications*, vol. 429, no. 1-2, pp. 75–80, 2012.

[32] M. E. Patiarroyo, A. Bermúdez, M. P. Alba et al., "IMPIPS: the immune protection-inducing protein structure concept in the search for stericelectron and topochemical principles for complete fully-protective chemically synthesised vaccine development," *PLoS One*, vol. 10, no. 4, article e0123249, 2015.

[33] M. E. Patiarroyo, M. A. Patiarroyo, L. Pabón, H. Curtidor, and L. A. Poloche, "Immune protection-inducing protein structures (IMPIPS) against malaria: the weapons needed for beating Odysseus," *Vaccine*, vol. 33, no. 52, pp. 7525–7537, 2015.
[54] National Research Council of the National Academies, *Guide for the Care and Use of Laboratory Animals*, Eighth edition, 2011.

[55] S. Dutta, A. Tewari, C. Balaji et al., “Strain-transcending neutralization of malaria parasite by antibodies against *Plasmodium falciparum* enolase,” *Malaria Journal*, vol. 17, no. 1, p. 304, 2018.

[56] M. T. Whary, N. Baumgarth, J. G. Fox, and S. W. Barthold, “*Biology and diseases of mice*,” in *Laboratory animal medicine* 2, J. G. Fox, L. C. Anderson, G. M. Otto, K. R. Pritchett-Corning, and M. T. Whary, Eds., pp. 43–149, Elsevier, 2015.

[57] N. T. Veith, T. Histing, M. D. Menger, T. Pohlemann, and T. Tschernig, “Helping prometheus: liver protection in acute hemorrhagic shock,” *Annals of Translational Medicine*, vol. 5, no. 10, p. 206, 2017.

[58] S. Awate, L. A. Babiuk, and G. Mutwiri, “Mechanisms of action of adjuvants,” *Frontiers in Immunology*, vol. 4, p. 114, 2013.

[59] P. J. Haley, “The lymphoid system: a review of species differences,” *Journal of Toxicologic Pathology*, vol. 30, no. 2, pp. 111–123, 2017.

[60] M. E. Patarroyo, M. P. Alba, C. Reyes, R. Rojas-Luna, and M. A. Patarroyo, “The Malaria Parasite’s Achilles’ Heel: Functionally-relevant Invasion Structures,” *Current Issues in Molecular Biology*, vol. 18, pp. 11–20, 2016.

**European Medicines Agency (EMA),** "Guideline on repeated dose toxicity," vol. 99, 2010.

**European Agency for the Evaluation of Medicinal Products (EMEA),** *Note for guidance on non-clinical local tolerance testing of medicinal products*, London, 2001.

**World Health Organization (WHO),** *Annex 1 WHO guidelines on nonclinical evaluation of vaccines*, 2005.

**World Health Organization (WHO),** *Handbook: Good Laboratory Practice (GLP): Quailty Practices for Regulated Non-clinical Research and Development, 2nd edition*, 2009.

**European Medicines Agency (EMA),** *Guideline on the principles of regulatory acceptability of 3Rs (replacement, reduction, refinement) testing approaches*, 2016.

**International Conference on Harmonisation (ICH),** "ICH S6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals," vol. 6, 2011.

**Ministerio de Salud de Colombia,** *Resolución Número 8430 de 1993*, Colombia, 1993.

**Congreso Nacional de Colombia,** *Ley 84 de 1989*, Congreso de Colombia, Colombia, 1989.

**American Veterinary Medical Association (AVMA),** *AVMA guidelines for the euthanasia of animals*, 2013.

**National Research Council of the National Academies,** *Guide for the Care and Use of Laboratory Animals*, Eighth edition, 2011.

**European Medicines Agency (EMA),** "ICH S6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals," vol. 6, 2011.

**National Research Council of the National Academies,** *Guide for the Care and Use of Laboratory Animals*, Eighth edition, 2011.

**World Health Organization (WHO),** *Annex 1 WHO guidelines on nonclinical evaluation of vaccines*, 2005.

**World Health Organization (WHO),** *Handbook: Good Laboratory Practice (GLP): Quality Practices for Regulated Non-clinical Research and Development, 2nd edition*, 2009.

**World Health Organization (WHO),** *Handbook: Good Laboratory Practice (GLP): Quality Practices for Regulated Non-clinical Research and Development, 2nd edition*, 2009.

**European Medicines Agency (EMA),** *Guideline on the principles of regulatory acceptability of 3Rs (replacement, reduction, refinement) testing approaches*, 2016.

**International Conference on Harmonisation (ICH),** "ICH S6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals," vol. 6, 2011.

**European Medicines Agency (EMA),** "Guideline on repeated dose toxicity," vol. 99, 2010.

**European Agency for the Evaluation of Medicinal Products (EMEA),** *Note for guidance on non-clinical local tolerance testing of medicinal products*, London, 2001.

**World Health Organization (WHO),** *Annex 1 WHO guidelines on nonclinical evaluation of vaccines*, 2005.